Healthcare M&A Update Q1 2026
MedTech CDMO M&A: Strong demand for capability-driven platform exansion
Global MedTech CDMO deal activity has moderated in 2025. The market has become more selective. Buyers prioritize technical capabilities, scalability and strategic fit over transaction volume.
Strategic buyers continue to lead most transactions. Private equity drives consolidation through platform building and add-on acquisitions.
Key insights at a glance
- Deal activity moderated in 2025, without indicating a decline in underlying demand.
- Design & development and assembly capabilities continue to anchor MedTech CDMO M&A activity.
- From a material perspective, deals focus on plastics, polymers, and multi-material capabilities.
- DACH remains one of Europe’s core hubs for MedTech CDMO activity.
- The region combines scale, precision, and deep engineering expertise.
- Larger MedTech CDMO transactions continue to command higher valuation multiples.
- M&A remains focused on platform expansion and targeted capability acquisitions.
Across DACH, the market remains fragmented and capability-driven. Most players are positioned as long-term partners to OEMs. This creates high switching costs and strong customer retention.
Explore our latest Healthcare M&A Update for detailed insights into the MedTech sector
Feel free to reach out to our experts to discuss any questions or areas of interest. We would be pleased to explore how Oaklins can create value for you through our strong international network. Our team is at your disposal to address your specific M&A and corporate finance objectives.
Your contact persons
Partner
View profile
Analyst
View profile